Literature DB >> 11342503

Effects of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis.

J Protheroe1, T Fahey, A A Montgomery, T J Peters.   

Abstract

OBJECTIVE: To investigate the effect of patients' preferences in the treatment of atrial fibrillation by using individualized decision analysis in which probability and utility assessments are combined into a decision tree.
DESIGN: Observational study based on interviews with patients.
SETTING: 8 general practices in Avon, England. PARTICIPANTS: 260 randomly selected patients aged 70 to 85 years with atrial fibrillation. MAIN OUTCOME MEASURES: Patients' treatment preferences regarding anticoagulation treatment (warfarin sodium) after individualized decision analysis; comparison of these preferences with treatment guidelines on the basis of comorbidity and absolute risk and compared with current prescription.
RESULTS: Of 195 eligible patients, 97 participated in decision making using decision analysis. Among these 97, the decision analysis indicated that 59 (61%; 95% confidence interval, 50%-71%) would prefer anticoagulation treatment, considerably fewer than those who would be recommended treatment according to guidelines. There was marked disagreement between the decision analysis and guideline recommendations (kappa> or =0.25). Of 38 patients whose decision analysis indicated a preference for anticoagulation, 17 (45%) were being prescribed warfarin; on the other hand, 28 (47%) of 59 patients were not being prescribed warfarin, although the results of their decision analysis suggested they wanted to be.
CONCLUSIONS: In the context of shared decision making, individualized decision analysis is valuable in a sizable proportion of elderly patients with atrial fibrillation. Taking account of patients' preferences would lead to fewer prescriptions for warfarin than under published recommendations. Decision analysis as a shared decision-making tool should be evaluated in a randomized controlled trial.

Entities:  

Keywords:  Empirical Approach; Professional Patient Relationship

Mesh:

Substances:

Year:  2001        PMID: 11342503      PMCID: PMC1071384          DOI: 10.1136/ewjm.174.5.311

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  26 in total

1.  Managing atrial fibrillation in elderly people.

Authors:  K M English; K S Channer
Journal:  BMJ       Date:  1999-04-24

2.  Thromboprophylaxis for atrial fibrillation.

Authors:  G Y Lip
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 3.  Decision analysis and the implementation of research findings.

Authors:  R J Lilford; S G Pauker; D A Braunholtz; J Chard
Journal:  BMJ       Date:  1998-08-08

4.  Primer on medical decision analysis: Part 3--Estimating probabilities and utilities.

Authors:  G Naglie; M D Krahn; D Naimark; D A Redelmeier; A S Detsky
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

Review 5.  Antithrombotic therapy in atrial fibrillation.

Authors:  A Laupacis; G Albers; J Dalen; M Dunn; W Feinberg; A Jacobson
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 6.  Partnerships with patients: the pros and cons of shared clinical decision-making.

Authors:  A Coulter
Journal:  J Health Serv Res Policy       Date:  1997-04

7.  Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation.

Authors:  A Howitt; D Armstrong
Journal:  BMJ       Date:  1999-05-15

8.  Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

Authors:  M Sudlow; R Thomson; B Thwaites; H Rodgers; R A Kenny
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

9.  Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials.

Authors: 
Journal:  Arch Intern Med       Date:  1998-06-22

10.  An evidence based approach to individualising treatment.

Authors:  P P Glasziou; L M Irwig
Journal:  BMJ       Date:  1995-11-18
View more
  7 in total

1.  More on patients' preferences in treating atrial fibrillation.

Authors:  A Montgomery; T Fahey; J Protheroe; T J Peters
Journal:  West J Med       Date:  2001-12

Review 2.  Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.

Authors:  Ekta Y Pandya; Beata Bajorek
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

3.  How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology.

Authors:  Andrew Lloyd; Emma McIntosh; Angela E Williams; Ad Kaptein; Klaus F Rabe
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

4.  Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.

Authors:  Mark H Eckman; Ruth E Wise; Katherine Naylor; Lora Arduser; Gregory Y H Lip; Brett Kissela; Matthew Flaherty; Dawn Kleindorfer; Faisal Khan; Daniel P Schauer; John Kues; Alexandru Costea
Journal:  Curr Med Res Opin       Date:  2015-03-13       Impact factor: 2.580

Review 5.  A systematic review of information in decision aids.

Authors:  Deb Feldman-Stewart; Sarah Brennenstuhl; Kathryn McIssac; Joan Austoker; Agathe Charvet; Paul Hewitson; Karen R Sepucha; Tim Whelan
Journal:  Health Expect       Date:  2007-03       Impact factor: 3.377

6.  Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting.

Authors:  Ekta Yogeshkumar Pandya; Elizabeth Anderson; Clara Chow; Yishen Wang; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 7.  Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review.

Authors:  Thomas Wilke; Sabine Bauer; Sabrina Mueller; Thomas Kohlmann; Rupert Bauersachs
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.